Literature DB >> 28937941

The Scheduling of Kratom and Selective Use of Data.

O Hayden Griffin1, Megan E Webb2.   

Abstract

Kratom is a traditional drug from Southeast Asia that has been an emerging new substance in the United States. On August 30, 2016, the DEA announced the intention to emergency schedule kratom into Schedule I. To support this decision, the DEA cited an increase in drug seizures of kratom and an increase in calls to poison control concerning kratom. However, a short time later, on October 12, 2016, the DEA withdrew the intent to schedule kratom after public and congressional backlash. The withdrawal by the DEA was somewhat unprecedented. To better understand both decisions, the current article examines the evidence the DEA cited to support their decision to emergency schedule kratom and the degree and type of media coverage of kratom to determine if a media-driven drug panic occurred.

Entities:  

Keywords:  Controlled Substances Act; Drug Enforcement Administration; drug panic; kratom

Mesh:

Substances:

Year:  2017        PMID: 28937941     DOI: 10.1080/02791072.2017.1371363

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  8 in total

Review 1.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

2.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

Review 3.  Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review.

Authors:  Jonathan Schimmel; Richard C Dart
Journal:  Drugs       Date:  2020-02       Impact factor: 11.431

4.  G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder.

Authors:  Anna M Gutridge; Meridith T Robins; Robert J Cassell; Rajendra Uprety; Kendall L Mores; Mee Jung Ko; Gavril W Pasternak; Susruta Majumdar; Richard M van Rijn
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

5.  Kratom-Induced Liver Injury: A Case Series and Clinical Implications.

Authors:  Mahesh Botejue; Gurjot Walia; Omar Shahin; Jyotsna Sharma; Rasiq Zackria
Journal:  Cureus       Date:  2021-04-25

6.  Evaluation of Kratom Opioid Derivatives as Potential Treatment Option for Alcohol Use Disorder.

Authors:  Anna M Gutridge; Soumen Chakraborty; Balazs R Varga; Elizabeth S Rhoda; Alexander R French; Arryn T Blaine; Quinten H Royer; Haoyue Cui; Jinling Yuan; Robert J Cassell; Márk Szabó; Susruta Majumdar; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2021-11-03       Impact factor: 5.988

Review 7.  Understanding Kratom Use: A Guide for Healthcare Providers.

Authors:  Marc T Swogger; Kirsten E Smith; Albert Garcia-Romeu; Oliver Grundmann; Charles A Veltri; Jack E Henningfield; Lorna Y Busch
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

8.  Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States.

Authors:  Walter Prozialeck; Alexandra Fowler; Joshua Edwards
Journal:  Toxics       Date:  2022-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.